NanoViricides Inc

$ 1.55

0.65%

30 Jul - close price

  • Market Cap 35,698,800 USD
  • Current Price $ 1.55
  • High / Low $ 1.59 / 1.53
  • Stock P/E N/A
  • Book Value 0.42
  • EPS -0.43
  • Next Earning Report -
  • Dividend Per Share N/A
  • Dividend Yield 0 %
  • Next Dividend Date -
  • ROA -0.50 %
  • ROE -0.90 %
  • 52 Week High 2.23
  • 52 Week Low 0.85

About

NanoViricides, Inc., a nanobiopharmaceutical company, discovers, develops and markets drugs for the treatment of viral infections. The company is headquartered in Shelton, Connecticut.

Analyst Target Price

$6.00

Quarterly Earnings

Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
Reported Date 2026-05-142026-02-172025-11-142025-09-032025-05-152025-02-142024-11-142024-09-272024-05-152024-02-142023-10-132023-08-30
Reported EPS -0.09-0.11-0.1-0.12-0.14-0.1391-0.228-0.19-0.16-0.18-0.17-0.3052
Estimated EPS -0.08-0.08-0.18-0.2-0.19-0.18-0.17-0.2-0.19-0.19-0.17-0.17
Surprise -0.01-0.030.080.080.050.0409-0.0580.010.030.010-0.1352
Surprise Percentage -12.5%-37.5%44.4444%40%26.3158%22.7222%-34.1176%5%15.7895%5.2632%0%-79.5294%

Next Quarterly Earnings

Reported Date
Fiscal Date Ending
Estimated EPS
Currency

Next Dividend Records

Dividend per share (year): -
Dividend Yield -
Next Dividend Date -
Ex-Dividend Date -

Recent News: NNVC

...
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

2026-08-03 16:10:44

NanoViricides, Inc. announced the closing of a $6 million registered direct offering where it sold 3,571,429 shares of common stock at $1.68 per share to a single institutional investor. Concurrently, the company issued Series A and Series B warrants to purchase an additional 3,571,429 shares each. The net proceeds will be used for working capital and general corporate purposes, advancing the company's clinical-stage antiviral drug development.

...
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

2026-08-03 03:13:02

NanoViricides, Inc. (NYSE American:NNVC) announced a registered direct offering to a single healthcare institutional investor for 3,571,429 shares of common stock at $1.68 per share, expecting to raise approximately $6 million. Concurrently, the company will issue Series A and Series B warrants to purchase an additional 3,571,429 shares each. The net proceeds will be used for working capital and general corporate purposes.

...
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

2026-08-01 14:39:19

NanoViricides, Inc. (NNVC) has announced the closing of a $6 million registered direct offering and a concurrent private placement. The offering involved the sale of 3,571,429 shares of common stock at $1.68 per share to a single healthcare institutional investor. Additionally, the company issued Series A and Series B warrants, with exercise prices of $1.75 and $2.00 respectively, to purchase up to 3,571,429 shares each.

NanoViricides issues warrants exercisable at US$1.75 in US$3.8 million registered direct offering

2026-07-31 03:09:49

NanoViricides has announced a registered direct offering of common shares and warrants, expecting to raise approximately US$3.8 million in gross proceeds. The offering includes 2,516,339 common shares, with each warrant exercisable at US$1.75 per share and expiring 5.5 years from issuance. The closing of this offering is targeted for around July 27, 2026.

NanoViricides Raises $3.8 Million in Registered Direct Offering; Adds Placement Agent and 30-Day Lock-Up

2026-07-30 10:40:27

NanoViricides successfully completed a registered direct offering, securing approximately $3.8 million in gross proceeds through the sale of common shares and pre-funded and common warrants. The company plans to allocate the net proceeds towards working capital, R&D, clinical trials, and strategic initiatives. Additionally, NanoViricides engaged D. Boral Capital as its exclusive placement agent and implemented 30-day post-closing lock-ups for its CEO and principal stockholder.

...
NanoViricides Inc (NNVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-07-28 15:13:02

This article from TradingKey provides a revenue breakdown for NanoViricides Inc (NNVC), covering business segments and regional revenue and profit contribution. It states that the relevant data has not yet been disclosed by the company. The article also includes current stock information for NNVC, showing a price of $1.650, an increase of 8.55%, and a market cap of $35.72 million.